Allergy Therapeutics has initiated a biomarker study at Imperial College London, which will aim to evaluate its novel virus like particle (VLP) based peanut allergy vaccine candidate.
The study will use human samples and a set of functional and molecular biomarkers to establish the starting dose to be used for its first-in-human phase I study of the VLP-based vaccine candidate.
In addition, this study will work as an early clinical predictor of efficacy of Allergy’s VLP platform, as well as support the investigational new drug application (IND) application for the vaccine.
Allergy Therapeutics plc (LON:AGY) is a market-leading, pioneering immunology business with specialist experience in the research and development of allergy treatments.